HealthWeight Loss
Eli Lilly's Retatrutide: A Promising New Weight Loss Drug
Eli Lilly's next-generation drug, retatrutide, has demonstrated significant weight loss in a crucial late-stage trial for patients with obes...
22 days ago
HealthWeight Loss
Eli Lilly's Orforglipron Shows Promising Weight Loss Results in Trials
10 months agoUS
Eli Lilly's investigational oral pill, orforglipron, is showing promising results in late-stage trials for obesity treatment, paving the way for a potential new option in the weight loss market. This development is particularly significant as it offers a needle-free alternative to existing GLP-1 receptor agonists.
Key Insights
•
In a Phase 3 trial, the highest dose of orforglipron led to an average weight loss of 12.4% (27.3 lbs) over 72 weeks compared to placebo. Why this matters: This level of weight loss can significantly improve health outcomes for individuals struggling with obesity.
•
59.6% of participants taking the highest dose of orforglipron achieved at least 10% body weight reduction, and 39.6% achieved at least 15%. Why this matters: Achieving these weight loss milestones is associated with reduced cardiovascular risk and improved metabolic health.
•
Orforglipron also demonstrated improvements in cardiovascular risk factors such as non-HDL cholesterol, triglycerides, and systolic blood pressure. Why this matters: Addressing these risk factors is crucial in managing the complications associated with obesity.
•
While generally well-tolerated, some patients discontinued treatment due to gastrointestinal side effects like nausea and vomiting. Why this matters: Managing side effects will be important for ensuring patient adherence and treatment success.
In-Depth Analysis
Orforglipron is an investigational once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist. The ATTAIN-1 trial (NCT05869903) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial that compared the efficacy and safety of orforglipron (6 mg, 12 mg, and 36 mg) as a monotherapy to a placebo in adults with obesity, or overweight with at least one comorbidity, excluding diabetes. The trial randomized 3,127 participants across multiple countries.
The results indicate that orforglipron could potentially transform obesity care by providing a convenient oral alternative to injectable treatments. Eli Lilly plans to submit orforglipron for regulatory review by the end of the year, with a potential launch in 2026. This oral option could help meet the demand for weight loss medications and address supply issues associated with existing injectable drugs, potentially reaching a broader patient population. The convenience of an oral medication could also make more physicians comfortable prescribing GLP-1s.
However, some analysts noted that the weight loss results were slightly lower than anticipated, and some doctors made note of the number of patients on the highest dose of the pill who discontinued treatment due to side effects. Detailed trial results will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 and published in a peer-reviewed journal. More phase three trial results on the pill will be shared later this year, including from a study on adults who have obesity or are overweight and have Type 2 diabetes.
FAQs
•
Q: How does orforglipron work?
Orforglipron is an oral GLP-1 receptor agonist that helps to promote weight loss and regulate blood sugar.
•
Q: What were the common side effects reported in the trial?
The most commonly reported side effects were gastrointestinal-related, such as nausea, constipation, diarrhea, and vomiting, generally mild-to-moderate in severity.
•
Q: When will orforglipron be available?
Eli Lilly expects to submit the data to regulators by the end of the year, with plans to launch the pill in 2026.
Key Takeaways
•
Orforglipron offers a potential needle-free alternative to injectable weight loss medications.
•
The drug has demonstrated significant weight loss and improvements in cardiovascular risk factors.
•
While side effects are a consideration, the convenience of an oral medication may make it a more accessible option for many patients.
This information impacts individuals struggling with obesity, healthcare providers, and the pharmaceutical industry, as it signals a potential shift in how obesity is managed.
Discussion
Do you think orforglipron will become a popular alternative to injectable weight loss medications? Let us know in the comments below!
Share this article with others who need to stay ahead of this trend!
Related Articles
HealthWeight Loss
Natural Ozempic Alternative Discovered by Stanford Scientists
A groundbreaking discovery by Stanford Medicine has identified a natural molecule, dubbed BRP, that mirrors the weight loss benefits of sema...
about 2 months ago
HealthWeight Loss
Jillian Michaels and Megyn Kelly Open Up About Their Health Journeys
Staying healthy involves consistent effort and the journey looks different for everyone. Jillian Michaels and Megyn Kelly have recently shar...
2 months ago
HealthWeight Loss
Wegovy Maker Challenges Weight-Loss Drug Copycats Amidst Telehealth Boom
The market for weight-loss drugs is heating up as Novo Nordisk, the maker of Wegovy, takes legal action against telehealth companies like Hi...
4 months ago
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer